Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
VG-161 by Virogin Biotech for Metastatic Hepatocellular Carcinoma (HCC): Likelihood of Approval
VG-161 is under clinical development by Virogin Biotech and currently in Phase II for Metastatic Hepatocellular Carcinoma (HCC). According to...
Data Insights
VG-161 by Virogin Biotech for Metastatic Hepatocellular Carcinoma (HCC): Likelihood of Approval
VG-161 is under clinical development by Virogin Biotech and currently in Phase II for Metastatic Hepatocellular Carcinoma (HCC). According to...